
The three-year fellowship, one of 61 in the United States, significantly will improve access to gynecologic cancer care for women in Alabama.
Let us help you connect with one of our doctors or other healthcare providers.
USA Health offers an extensive network of physicians and other healthcare providers through USA Physicians Group, the region’s largest multispecialty practice, and several other affiliated physician practices.
At USA Health, we treat people. In doing so, we want to understand your unique needs so our doctors and other providers can design a plan of care specifically for you. Use the field below to search for a specific service, treatment, specialty or provider.
As an academic health center, USA Health actively engages in the latest clinical trials to improve care for all patients.
Need help? Try our Patient Navigator or call (251) 434-3711
Whether you’re an existing patient or new patient, you can find more information about USA Health services and programs below.
Learn more information about USA Health, from special events and volunteer opportunities to job openings.
Let us help you connect with one of our doctors or other healthcare providers.
USA Health offers an extensive network of physicians and other healthcare providers through USA Physicians Group, the region’s largest multispecialty practice, and several other affiliated physician practices.
At USA Health, we treat people. In doing so, we want to understand your unique needs so our doctors and other providers can design a plan of care specifically for you. Use the field below to search for a specific service, treatment, specialty or provider.
As an academic health center, USA Health actively engages in the latest clinical trials to improve care for all patients.
Whether you’re an existing patient or new patient, you can find more information about USA Health services and programs below.
Learn more information about USA Health, from special events and volunteer opportunities to job openings.
Rodney P. Rocconi, M.D., joined Mitchell Cancer Institute (MCI) as a physician-scientist in the Gynecologic Oncology Service in 2007. He was the first MCI Abraham A. Mitchell Cancer Research Scholar. He specializes in the management of cancers of the ovary, uterus, cervix and lower genital tract. As the Associate Director for Clinical Research, Dr. Rocconi provides leadership and medical expertise to the clinical trials department, reviews and designs clinical research protocols, evaluates safety and efficacy data, analyzes and summarizes data for presentation to regulatory agencies, and provides strategic guidance on non-regulatory clinical trial plans. He is the recipient of the Gynecologic Cancer Foundation Ovarian Cancer Research Award and the Gynecologic Oncology Young Investigator Research Award. Dr. Rocconi also serves as a scientific expert reviewer for the U.S. Department of Defense Ovarian Cancer Research Program.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)
Patients with Endometrial Carcinoma
Abemaciclib and Letrozole to Treat Endometrial Cancer
Patients with Endometrial Carcinoma
A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
Treatment for Advanced Solid Tumors
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors
Treatment for Solid Tumors
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (anti–PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS
Treatment for Cervical Cancer
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.
Treatment for Uterine / Vaginal Cancer
The three-year fellowship, one of 61 in the United States, significantly will improve access to gynecologic cancer care for women in Alabama.
The Vigil vaccine is a genetically engineered vaccine made from cancer cells acquired from patients during surgery.
African-American patients with advanced ovarian cancer were found to have a pre-existing immune response linked to worse survival rates compared with their white counterparts, according to research led by Dr. Rodney P. Rocconi, a gynecologic oncologist and interim director of the USA Health Mitchell Cancer Institute.